These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22918158)

  • 21. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.
    McGready R; Tan SO; Ashley EA; Pimanpanarak M; Viladpai-Nguen J; Phaiphun L; Wüstefeld K; Barends M; Laochan N; Keereecharoen L; Lindegardh N; Singhasivanon P; White NJ; Nosten F
    PLoS Med; 2008 Dec; 5(12):e253. PubMed ID: 19265453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.
    Djimdé AA; Tekete M; Abdulla S; Lyimo J; Bassat Q; Mandomando I; Lefèvre G; Borrmann S;
    Antimicrob Agents Chemother; 2011 Sep; 55(9):3994-9. PubMed ID: 21670177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
    Tarning J; McGready R; Lindegardh N; Ashley EA; Pimanpanarak M; Kamanikom B; Annerberg A; Day NP; Stepniewska K; Singhasivanon P; White NJ; Nosten F
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3837-46. PubMed ID: 19564366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
    McGready R; Stepniewska K; Lindegardh N; Ashley EA; La Y; Singhasivanon P; White NJ; Nosten F
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1021-31. PubMed ID: 17053895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    J Clin Pharmacol; 2020 Mar; 60(3):351-360. PubMed ID: 31549442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
    Tiono AB; Tinto H; Alao MJ; Meremikwu M; Tshefu A; Ogutu B; Ouedraogo A; Lingani M; Cousin M; Lefèvre G; Jain JP; Duparc S; Hamed K
    Malar J; 2015 Apr; 14():157. PubMed ID: 25886021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
    Gerardin J; Eckhoff P; Wenger EA
    BMC Infect Dis; 2015 Mar; 15():144. PubMed ID: 25887935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artemether-lumefantrine: an option for malaria.
    Stover KR; King ST; Robinson J
    Ann Pharmacother; 2012 Apr; 46(4):567-77. PubMed ID: 22496476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
    Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
    Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coartemether (artemether and lumefantrine): an oral antimalarial drug.
    Wernsdorfer WH
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):181-96. PubMed ID: 15482185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
    Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
    Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product.
    Minzi OM; Marealle IA; Shekalaghe S; Juma O; Ngaimisi E; Chemba M; Rutaihwa M; Abdulla S; Sasi P
    Malar J; 2013 May; 12():174. PubMed ID: 23718725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Griffin S; Kose K; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5306-13. PubMed ID: 21876056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
    Bassat Q
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1325. PubMed ID: 22216359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.
    Adegbola A; Abutaima R; Olagunju A; Ijarotimi O; Siccardi M; Owen A; Soyinka J; Bolaji O
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
    Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
    Ezzet F; Mull R; Karbwang J
    Br J Clin Pharmacol; 1998 Dec; 46(6):553-61. PubMed ID: 9862244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.